Expression of CD14+ monocytes and CD163+ macrophages in patients with chronic hepatitis C and their relationship with the severity of liver fibrosis

Abstract

Abstract: Objective To investigate the expression of CD14⁺ monocytes and CD163⁺ macrophages in patients with chronic hepatitis C and their relationship with the severity of liver fibrosis. Methods A total of 83 patients with chronic hepatitis C and 64 healthy subjects were selected between April 2018 and November 2022. The clinical features, the expression of CD163 in liver tissue, the concentration of serum CD163, the proportion of CD14⁺ cells and the proportion of CD14⁺ cells expressing different kinds of cytokines were compared. Results The level of ALT and AST of chronic hepatitis C group were (84.6±9.1) U/L and (69.3±7.2) U/L, which was significantly higher than that in healthy control group [(28.4±1.7) U/L and (22.5±6.9) U/L] (P<0.05). The concentration of serum CD163 and the proportion of CD14⁺ cells, the number of CD163⁺ cells, concentration of serum CD163⁺ and CD14⁺ cell proportion of F<2 patients were 38.2±4.7, (73.6±2.1) μg/L and (73.7±3.2) %, which was significantly higher than that in healthy control group [12.5±1.3, (50.1±2.6) ?g/L and (61.0±8.4) %] (P<0.05). The number of CD163⁺ cells, concentration of serum CD163⁺ and CD14⁺ cell proportion of F≥2 patients were 74.9±8.0, (95.4±9.8) μg/L and (79.2±5.5) %, which was significantly higher than that in healthy control group and F<2 patients. CD14⁺ cells expressing IL-2, IL-4, IFN-γ, IL-6, IL-8 and TNF-α of F<2 patients were (4.2±1.2) %, (3.8±1.1) %, (3.8±1.0) %, (3.7±1.3) %, (4.0±1.4) % and (6.7±3.6) %, which was significantly higher than that in healthy control group [(0.9±0.1) %, (1.1±0.2) %, (1.8±0.4) %, (1.6±0.6) %, (1.7±0.7) % and (4.6±2.1) %] P<0.05). CD14⁺ cells expressing IL-2, IFN-γ, IL-8 and TNF-α of F≥2 patients were (2.2±0.8) %, (2.1±0.5) %, (5.6±2.0) % and (6.9±3.2) %, which was significantly higher than that in healthy control group. CD14⁺ cells expressing IL-8 was (5.6±2.0) %, which was significantly higher than that in F≥2 patients. Conclusion CD14⁺ monocytes and CD163⁺ macrophages are involved in the process of liver fibrosis in patients with chronic hepatitis C.

Key words: Chronic hepatitis C, Monocytes, Macrophages

HE Yu, ZHANG Zhi-hong, OUYANG Hui, LU Shi. Expression of CD14⁺ monocytes and CD163⁺ macrophages in patients with chronic hepatitis C and their relationship with the severity of liver fibrosis[J]. Chinese Hepatolgy, 2024, 29(4): 432-435.

References

[1] Tsai WC, Chiang HC, Chiu YC, et al. Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment[J]. Life (Basel), 2023, 13(10):1964.
[2] Zakurdaeva K, Tsimafeyeu I. Immunotherapy in cancer patients with chronic hepatitis C viral infection[J]. J Cancer Res Ther, 2023, 19(5): 1093-1097.
[3] Nunes PF, da Cruz Coelho E, da Silva JR, et al. Hepatitis C and Human Pegivirus Coinfection in Patients with Chronic Hepatitis C from the Brazilian Amazon Region: Prevalence, Genotypes and Clinical Data[J]. Viruses, 2023, 15(9):1892.
[4] Zhang F, Fan L, Liu Q, et al. Comprehensive immune cell analysis of human menstrual-blood-derived stem cells therapy to concanavalin A hepatitis[J]. Front Immunol, 2022, 13: 974387.
[5] Peng B, Li H, Liu K, et al. Intrahepatic macrophage reprogramming associated with lipid metabolism in hepatitis B virus-related acute-on-chronic liver failure[J]. J Transl Med, 2023, 21(1): 419.
[6] Zhu Y, Liu Y, Ma Y, et al. Macrophage autophagy deficiency-induced CEBPB accumulation alleviates atopic dermatitis via impairing M2 polarization[J]. Cell Rep, 2023, 42(11): 113430.
[7] Li Z, Cao Z, Li N, et al. M2 Macrophage-Derived Exosomal lncRNA MIR4435-2HG Promotes Progression of Infantile Hemangiomas by Targeting HNRNPA1. Int J Nanomedicine, 2023, 18: 5943-5960.
[8] Huang X, Deng Y, Xiao J, et al. Genetically engineered M2-like macrophage-derived exosomes for P. gingivalis-suppressed cementum regeneration: From mechanism to therapy[J]. Bioact Mater, 2024, 32: 473-487.
[9] Deswal B, Bagchi U, Kapoor S. Curcumin Suppresses M2 Macrophage-derived Paclitaxel Chemoresistance through Inhibition of PI3k-AKT/STAT3 Signaling[J]. Anticancer Agents Med Chem, 2024,24(2):146-156.
[10] Edwards CL, Engel JA, De Labastida Rivera F, et al. A molecular signature for IL-10-producing Th1 cells in protozoan parasitic diseases[J]. JCI Insight, 2023,8(24):e169362.
[11] O′Neal KA, Zeltner SL, Foscue CL, et al. Bhlhe40 limits early IL-10 production from CD4(+) T cells during Plasmodium yoelii 17X infection[J]. Infect Immun, 2023: e0036723.
[12] Khan MA, Ashoor GA, Shamma T, et al. IL-10 Mediated Immunomodulation Limits Subepithelial Fibrosis and Repairs Airway Epithelium in Rejecting Airway Allografts[J]. Cells, 2021, 10(5):1248.
[13] Kurosaki F, Uchibori R, Sehara Y, et al. AAV6-Mediated IL-10 Expression in the Lung Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice[J]. Hum Gene Ther, 2018, 29(11): 1242-1251.
[14] Hanouneh IA, Zein NN, Lopez R, et al. IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens[J]. Int J Organ Transplant Med, 2010, 1(1): 7-14.
[15] Maranatha D, Hasan H, Bakhtiar A, et al. Association of TNF-alpha, TGF-beta1, amphiregulin, IL-2, and EGFR WITH pulmonary fibrosis in COVID-19[J]. J Infect Public Health, 2022, 15(10): 1072-1075.

Expression of CD14⁺ monocytes and CD163⁺ macrophages in patients with chronic hepatitis C and their relationship with the severity of liver fibrosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LIU Ya-guang, HU Lian-zhi, DONG Yi-xia. Monocyte subsets and phenotypes in treatment Naive chronic hepatitis C patients treated with daclatasvir and sofosbuvir [J]. Chinese Hepatolgy, 2024, 29(4): 440-443.
[2]	ZHAO Ya-lin, SHEN Chuan, WEI Meng-ping, ZHAO Cai-yan. The impact of different antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C [J]. Chinese Hepatolgy, 2024, 29(2): 182-188.
[3]	LIU Li, LI Mei, CHANG Li-xian, LIU Chun-yun, LI Hui-min, FANG Ming, LI Jun-yi. Clinical analysis of 5 children cases of chronic hepatitis C genotype 1b treated with elbasvir/grazoprevir [J]. Chinese Hepatolgy, 2023, 28(9): 1041-1043.
[4]	SONG Jie, NIE Hong, CHI Hui, GUO Rui-fang. Clinical value analysis of serum macrophage inhibitory factor-1 level in patients with chronic hepatitis C (CHC) genotype 1b [J]. Chinese Hepatolgy, 2023, 28(8): 950-952.
[5]	QIN Yuan-feng, SHI Hai-yan, HUANG Zhong-qiang. Characteristics and clinical significance of peripheral blood lymphocyte subsets in patients with chronic hepatitis C [J]. Chinese Hepatolgy, 2023, 28(6): 683-687.
[6]	YAN Jing-quan, LIU Juan, LU Xue-lan, LAN Yun-cui, LIN Zhan-zhou. Effect of direct antivirals on liver fibrosis in patients with persistently virologically responsive chronic hepatitis C [J]. Chinese Hepatolgy, 2023, 28(5): 530-533.
[7]	FENG Wei-wei, KONG Yan, KANG Ru. Evaluation of clinical characteristics and prognosis in patients with chronic hepatitis C complicated with metabolic-related fatty liver disease [J]. Chinese Hepatolgy, 2023, 28(5): 534-536.
[8]	LIU Huang-cun, LI You-lei, LIU Yong-cheng. Influence of hepatitis E virus infection on the severity of chronic hepatitis C patients [J]. Chinese Hepatolgy, 2023, 28(5): 537-540.
[9]	TONG Yi, HU Su-xia, WANG Ran, DAI Jing-jing. Expression of TIM-3 and PD-1 at immune checkpoint in patients with chronic hepatitis C treated with sophobuvir/Vipartamivir and its clinical significance [J]. Chinese Hepatolgy, 2023, 28(12): 1455-1458.
[10]	SU Jing-bo, CAO Guang-hua. Analysis of the efficacy and safety of direct antiviral drugs combined with ribavirin in elderly patients with compensated liver cirrhosis caused by genotype 1b chronic hepatitis C [J]. Chinese Hepatolgy, 2023, 28(12): 1459-1461.
[11]	DENG Hao-hui, LOU Yan, LI Xiao-qiang, QIU Jiu-xiang. The relationship between single nucleotide polymorphisms of ITPA gene and thrombocytopenia induced by pegylated interferon therapy in chronic hepatitis C and chronic hepatitis B patients [J]. Chinese Hepatolgy, 2023, 28(1): 95-99.
[12]	SHI Dong-mei, XIANG Xiao-gang, ZHAO Gang-de, WANG Xiao-lin. Clinical features and prognosis of hepatitis C-associated hepatocellular carcinoma [J]. Chinese Hepatolgy, 2022, 27(6): 628-633.
[13]	HU Chun-xia,YANG Jiao-nan, ZHANG Feng-xiao, HU Jing-hua. Effect of comorbid type 2 diabetes mellitus on the antiviral response of interferon combined with ribavirin in patients with chronic hepatitis C [J]. Chinese Hepatolgy, 2022, 27(5): 553-556.
[14]	YE Fei-xiang, LI Jing, LIU Jing-rui, LIU Pei, DU Yun-fei. Effect of direct acting antiviral treatment based on sofosbuvir on the dynamic changes of serum cytokines in chronic hepatitis C patients [J]. Chinese Hepatolgy, 2022, 27(11): 1194-1197.
[15]	WANG Yu, ZHANG Chun-pan, WANG Yan, LIU Li-wei, LI Ke-xin, MA Zi-kun, JIA Ji-dong, WANG Jia-bo, ZHAO Xin-yan. Improvement effect of polygoni multiflori radix praeparatac in PD-1 knockout mice with liver injury induced by anti-CTLA-4 [J]. Chinese Hepatolgy, 2022, 27(1): 33-37.